US Pres Obama's new health plan melds House and Senate Bills, with implications for Pharma and generics, in a $950-billion overhaul
The proposal that US President Barack Obama will bring to his Thursday (February 25 health 'summit' with congressional leaders to help thrash out health care reform which has become stalled since the loss of the Democrat Senate seat in Massachusetts on January 19 - contains many of the ideas from the bills already passed by the Democratic House of Representatives and the Senate, including a mandate that individuals buy insurance and a promise to "end discrimination" from pre-existing conditions.
President Obama's revised health care plan would cost $950 billion over the next decade and would require the pharmaceutical industry to pay $10 billion more in fees over 10 years starting in 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze